Organisation:
Department:
Homepage:
Interests:
David is CEO of Aurum Biosciences Ltd, a company that aims to bring the first clinical stage perflurocarbon oxygen carrier (ABL-101) to market, with opportunities in stroke, spinal cord injury, cardiac arrest, heart attack, inflammation imaging & oncology.
David who became CEO in January 2023 started out his career working in the NHS in medical physics. After gaining experience in electronics, radiotherapy & nuclear medicine he settled into a career in magnetic resonance imaging (MRI). Here he worked on numerous clinical research collaborations in the areas of oncology, head injury, post-traumatic stress disorder, depression, dementia and epilepsy.
David also had clinical responsibilities which included setting up and running the functional MRI clinical service, and image analysis services and providing safety advice as an MRI Safety Expert. David worked as a registered clinical scientist and was a member of the Institute of Physics & Engineering in Medicine.
During his time in the NHS he was a principal investigator on a Scottish Enterprise Proof of Concept (PoC) project which aimed to commercialise oxygen delivery as both a diagnostic and acute therapeutic in stroke. Following the success of that project David became a co-founder of Aurum which was created with funding from The Wellcome Trust, an angel group and private investors. It currently aims to run Phase 2 trials in Q4 of 2025, with the potential of three initial trials in acute stroke, spinal cord injury and inflammation imaging.
From an early stage in the PoC project David took a keen interest in the commercial aspects by taking a number of courses to strengthen his knowledge in this area. This included the IGNITE course held in Cambridge, UK and the Entrepreneurship Development Program (EDP) held at MIT Cambridge MA.
David has continued to foster his interests in commercialisation. From 2015 he worked as Director of Project Management for Aurum before becoming CEO in 2023. David has taken responsibility for many areas of the business, including fund raising, intellectual property protection, legal negotiations, business development and pharmaceutical manufacturing operations.